title: Safety, tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: a 26-week, open-label, continuation study.
abstract: OBJECTIVE
  The purpose of this study was to describe the safety, tolerability, and efficacy of quetiapine monotherapy continued for up to 26-weeks in youth with schizophrenia or bipolar I disorder.
  
  
  METHODS
  Medically healthy boys and girls with a baseline Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV-TR) diagnosis of schizophrenia (ages 13-17 years) or a manic episode of bipolar I disorder (ages 10-17 years) who participated in one of two acute, double-blind, placebo-controlled studies of immediate-release quetiapine were potentially eligible to enroll in a 26-week, open-label study. During the open-label study, quetiapine was flexibly dosed at 400-800 mg/day, with options to reduce dosing to 200 mg/day based on tolerability. Safety and tolerability outcomes assessed from open-label baseline to week 26 included adverse events (AEs), metabolic/laboratory parameters, extrapyramidal symptoms, suicidality, and vital signs.
  
  
  RESULTS
  Of 381 patients enrolled in the open-label study (n=176, schizophrenia; n=205, bipolar disorder diagnosis), 237 patients (62.2%) completed the 26-week study period (71.0%, schizophrenia; 54.6%, bipolar disorder). The most common AEs reported during the study included somnolence, headache, sedation, weight increase, and vomiting. A total of 14.9% of patients experienced a shift to potentially clinically significant low levels of high-density lipoprotein cholesterol and 10.2% of patients experienced a shift to potentially clinically significant high triglyceride levels. Weight gain ≥ 7% was reported in 35.6% of patients between open-label baseline and final visit. After adjustment for normal growth, 18.3% of study participants experienced clinically significant weight gain (i.e., increase in body mass index ≥ 0.5 standard deviations from baseline).
  
  
  CONCLUSIONS
  In this 26-week study, quetiapine flexibly dosed at 400-800 mg/day, with options to reduce dosing based on tolerability, was generally safe and well tolerated in youth. Clinicians should monitor lipid profiles and weight gain in youth with schizophrenia or bipolar disorder during treatment with quetiapine.
authors.affiliation: 1 Johns Hopkins Medicine and the Kennedy Krieger Institute , Baltimore, Maryland.
authors.forename: Robert L
authors.initials: RL
authors.lastname: Findling
authors.forename: Sanjeev
authors.initials: S
authors.lastname: Pathak
authors.forename: Willie R
authors.initials: WR
authors.lastname: Earley
authors.forename: Sherry
authors.initials: S
authors.lastname: Liu
authors.forename: Melissa
authors.initials: M
authors.lastname: DelBello
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy*; D002648:Child; D003987:Dibenzothiazepines / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D000069348:Quetiapine Fumarate; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate
references.citation: J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8
references.pmid: 9204677
references.citation: Bipolar Disord. 2007 Dec;9(8):868-75
references.pmid: 18076536
references.citation: Bipolar Disord. 2009 Nov;11(7):687-700
references.pmid: 19839994
references.citation: J Clin Psychiatry. 2007 May;68(5):789-95
references.pmid: 17503991
references.citation: J Clin Psychiatry. 2011 Nov;72(11):1452-64
references.pmid: 22054050
references.citation: J Clin Psychiatry. 2009 Oct;70(10):1441-51
references.pmid: 19906348
references.citation: Dev Psychopathol. 2006 Fall;18(4):1231-46
references.pmid: 17064436
references.citation: Br J Psychiatry. 1989 May;154:672-6
references.pmid: 2574607
references.citation: Am J Psychiatry. 2007 Jul;164(7):1035-43
references.pmid: 17606655
references.citation: Schizophr Bull. 2000;26(4):801-16
references.pmid: 11087013
references.citation: J Child Adolesc Psychopharmacol. 2012 Oct;22(5):327-42
references.pmid: 23083020
references.citation: Am J Psychiatry. 2008 Nov;165(11):1420-31
references.pmid: 18794207
references.citation: J Affect Disord. 1994 Aug;31(4):281-94
references.pmid: 7989643
references.citation: Dev Psychopathol. 2001 Summer;13(3):581-98
references.pmid: 11523849
references.citation: J Child Adolesc Psychopharmacol. 2009 Dec;19(6):611-21
references.pmid: 20035579
references.citation: Expert Opin Pharmacother. 2010 Feb;11(2):195-205
references.pmid: 20088741
references.citation: Am J Psychiatry. 2011 Dec;168(12):1266-77
references.pmid: 22193671
references.citation: Eur Neuropsychopharmacol. 2011 Aug;21(8):621-45
references.pmid: 20702068
references.citation: Am J Psychiatry. 2007 Oct;164(10):1547-56
references.pmid: 17898346
references.citation: Biol Psychiatry. 2008 Mar 1;63(5):524-9
references.pmid: 17651705
references.citation: Bipolar Disord. 2005 Dec;7(6):525-35
references.pmid: 16403178
references.citation: Br J Psychiatry. 1978 Nov;133:429-35
references.pmid: 728692
references.citation: Child Adolesc Psychiatry Ment Health. 2008 Feb 27;2(1):6
references.pmid: 18304312
references.citation: JAMA. 2009 Oct 28;302(16):1765-73
references.pmid: 19861668
references.citation: Am J Psychiatry. 2008 Nov;165(11):1432-41
references.pmid: 18765484
references.citation: J Child Adolesc Psychopharmacol. 2001 Winter;11(4):415-24
references.pmid: 11838824
references.citation: Acta Psychiatr Scand Suppl. 1970;212:11-9
references.pmid: 4917967
references.citation: Bipolar Disord. 2010 Mar;12(2):172-84
references.pmid: 20402710
references.citation: J Am Acad Child Adolesc Psychiatry. 2003 Apr;42(4):386-405
references.pmid: 12649626
references.citation: Schizophr Bull. 1987;13(2):261-76
references.pmid: 3616518
references.citation: J Am Acad Child Adolesc Psychiatry. 2009 Jan;48(1):60-70
references.pmid: 19057413
references.citation: J Child Adolesc Psychopharmacol. 2011 Dec;21(6):517-35
references.pmid: 22166172
references.citation: J Child Adolesc Psychopharmacol. 2009 Oct;19(5):553-61
references.pmid: 19877980
references.citation: J Youth Adolesc. 1980 Jun;9(3):271-80
references.pmid: 24318082
references.citation: J Child Adolesc Psychopharmacol. 2007 Dec;17(6):768-78
references.pmid: 18315449
references.citation: Bipolar Disord. 2010 Sep;12(6):593-605
references.pmid: 20868458
references.citation: Arch Gen Psychiatry. 2006 Feb;63(2):175-83
references.pmid: 16461861
references.citation: Arch Gen Psychiatry. 1983 Nov;40(11):1228-31
references.pmid: 6639293
references.citation: Biol Psychiatry. 2004 May 1;55(9):875-81
references.pmid: 15110730
references.citation: J Clin Psychiatry. 2009 Dec;70(12):e45
references.pmid: 20141702
references.citation: J Clin Psychiatry. 2000 Apr;61(4):252-60
references.pmid: 10830145
references.citation: J Am Acad Child Adolesc Psychiatry. 2010 Jun;49(6):583-94; quiz 632
references.pmid: 20494268
references.citation: Arch Gen Psychiatry. 1984 Feb;41(2):157-61
references.pmid: 6696597
references.citation: J Child Adolesc Psychopharmacol. 2008 Aug;18(4):317-26
references.pmid: 18759641
references.citation: Arch Gen Psychiatry. 2006 Oct;63(10):1130-8
references.pmid: 17015815
references.citation: Curr Opin Psychiatry. 2010 Jul;23(4):304-10
references.pmid: 20502331
references.citation: Psychiatry Res. 1997 Dec 5;73(3):159-71
references.pmid: 9481807
references.citation: Schizophr Bull. 2005 Jul;31(3):769-80
references.pmid: 16123530
references.citation: Arch Pediatr Adolesc Med. 2008 Oct;162(10):929-35
references.pmid: 18838645
references.citation: J Clin Psychiatry. 2013 Jan;74(1):e100-9
references.pmid: 23419231
references.citation: Bipolar Disord. 2009 Aug;11(5):483-93
references.pmid: 19624387
references.citation: J Am Acad Child Adolesc Psychiatry. 1995 Jun;34(6):724-31
references.pmid: 7608045
references.citation: J Ment Health. 2010 Apr;19(2):113-26
references.pmid: 20433320